Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.75 Insider Own5.84% Shs Outstand41.08M Perf Week-0.62%
Market Cap33.46M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float38.68M Perf Month-25.95%
Income-69.94M PEG- EPS next Q-0.46 Inst Own43.55% Short Float0.19% Perf Quarter-4.31%
Sales0.00M P/S- EPS this Y38.89% Inst Trans0.50% Short Ratio0.10 Perf Half Y-8.48%
Book/sh3.47 P/B0.24 EPS next Y-5.33% ROA-36.64% Short Interest0.07M Perf Year-10.40%
Cash/sh3.20 P/C0.25 EPS next 5Y5.20% ROE-41.21% 52W Range0.74 - 1.76 Perf YTD-8.38%
Dividend Est.- P/FCF- EPS past 5Y- ROI-48.76% 52W High-53.72% Beta1.22
Dividend TTM- Quick Ratio8.57 Sales past 5Y0.00% Gross Margin- 52W Low10.04% ATR (14)0.09
Dividend Ex-Date- Current Ratio8.57 EPS Y/Y TTM3.33% Oper. Margin0.00% RSI (14)31.44 Volatility5.00% 7.74%
Employees215 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom2.25 Target Price4.12
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q23.76% Payout- Rel Volume0.24 Prev Close0.80
Sales Surprise- EPS Surprise-217.24% Sales Q/Q- EarningsApr 04 BMO Avg Volume783.53K Price0.81
SMA20-22.92% SMA50-27.69% SMA200-15.10% Trades Volume184,532 Change1.53%
Date Action Analyst Rating Change Price Target Change
Apr-05-24Downgrade Piper Sandler Overweight → Neutral $8 → $2
Apr-26-21Initiated Piper Sandler Overweight $25
Apr-26-21Initiated Oppenheimer Outperform $23
Apr-26-21Initiated JP Morgan Underweight $11
Apr-26-21Initiated Chardan Capital Markets Buy $27
Apr-26-21Initiated BofA Securities Buy $20
Apr-04-24 11:53AM
Feb-05-24 07:00AM
Dec-18-23 07:00AM
04:30PM Loading…
Nov-13-23 04:30PM
Oct-24-23 12:30PM
Sep-22-23 04:30PM
Sep-13-23 12:05PM
Sep-06-23 09:40AM
Aug-10-23 11:50AM
Aug-04-23 07:00AM
Jun-12-23 08:00AM
May-21-23 10:03AM
07:15AM Loading…
May-10-23 07:15AM
Apr-25-23 06:00PM
Apr-22-23 09:45AM
Apr-17-23 08:00AM
Mar-07-23 07:00AM
Feb-02-23 09:40AM
Jan-17-23 09:40AM
Dec-20-22 08:30AM
Dec-06-22 06:00AM
Nov-30-22 06:05PM
Nov-22-22 08:00AM
Nov-13-22 07:48AM
Nov-08-22 07:00AM
12:00PM Loading…
Nov-01-22 12:00PM
Oct-06-22 08:30AM
Sep-07-22 01:15PM
Aug-31-22 12:53PM
Aug-26-22 01:34PM
Aug-25-22 11:53AM
Aug-24-22 01:33PM
Aug-23-22 01:53PM
Aug-19-22 12:32PM
Aug-16-22 10:09AM
Aug-09-22 07:00AM
Aug-01-22 06:00AM
Jul-21-22 08:00AM
Jun-30-22 08:00AM
Jun-21-22 08:30AM
Jun-06-22 08:40AM
May-10-22 07:00AM
May-09-22 07:00AM
May-04-22 08:00AM
May-03-22 08:00AM
Apr-14-22 11:27AM
Apr-12-22 07:30AM
Apr-05-22 08:00AM
Apr-04-22 08:00AM
Mar-08-22 08:00AM
Mar-01-22 09:00AM
Feb-07-22 07:30AM
Jan-13-22 07:30AM
Dec-28-21 04:09AM
Dec-21-21 08:00AM
Dec-20-21 08:00AM
Dec-09-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 08:15AM
Nov-09-21 08:00AM
Oct-22-21 07:30AM
Oct-12-21 08:00AM
Oct-01-21 08:00AM
Sep-29-21 06:15AM
Sep-02-21 08:30AM
Aug-25-21 08:00AM
Aug-10-21 07:00AM
Jul-26-21 03:00PM
Jul-01-21 08:00AM
Jun-04-21 09:00AM
May-11-21 07:00AM
May-06-21 08:00AM
May-05-21 08:30AM
May-03-21 08:00AM
Apr-10-21 08:30AM
Apr-06-21 04:01PM
Mar-31-21 02:01PM
Mar-30-21 07:00PM
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.